西部证券（002673）发布研报称，今年以来医药行业细分板块表现分化，医疗器械、医院板块持续受到 宏观消费疲软、医保资金收紧、集采影响延续等因素的影响，业绩有所承压，目前医疗设备、医院、线 下药店、医药流通、中药目前估值分位点处于10年历史低值，处于超跌位置。在国家推出多项政策大力 支持创新器械，加强基层医疗服务建设的背景下，该行认为医药板块仍具备较大潜力，推荐关注医疗器 械、医疗消费及线下药店方向。 今年以来，多项政策颁布推动大规模设备更新和创新器械。该行认为以旧换新能够加速医疗设备下沉和 医疗需求的释放，院内业务有望回暖，2025年高端医疗设备行业有望保持高景气。且在2021-2024年板 块回调较多的情况下，估值具备较强性价比。考虑政策环境、集采概率、行业增速和国产化率等多重因 素，建议关注优质细分赛道：血透行业、超声行业、内窥镜行业、口腔产业链等。推荐标的：迈瑞医疗 （300760）、联影医疗、海泰新光、山外山、澳华内镜、时代天使、爱迪特（301580）等，建议关注： 威高血净（603014）、天益医疗（301097）、三鑫医疗（300453）等。 医疗消费，看好低估值下医院服务的恢复和基层医疗服务建 ...

Core Viewpoint - The company, Northern Heavy Industries Group Co., Ltd. (北方股份), is experiencing growth in its stock price and aims to achieve significant revenue targets in the coming years, driven by its expanding international market presence and improved product competitiveness. Group 1: Stock Performance and Market Position - As of May 30, 2025, the stock price of Northern Heavy Industries closed at 22.33 yuan, up 7.1% from the previous week [1] - The stock reached a nearly one-year high of 24.99 yuan on May 28, 2025, with a market capitalization of 3.796 billion yuan, ranking 95th in the specialized equipment sector [1] - The company ranks 3593rd out of 5146 in the A-share market [1] Group 2: Business Operations and Market Strategy - The company's primary business includes the research, production, sales, and service of mining vehicles, with a marketing network that spans across China and extends globally to 67 countries and regions [1] - Northern Heavy Industries has seen rapid growth in its overseas market, leveraging direct sales and partnerships, supported by the "going out" policy of Chinese enterprises [1] - The company is narrowing the performance gap with world-class mining vehicle manufacturers like Caterpillar and Komatsu [1][6] Group 3: Financial Performance and Projections - In 2024, the company achieved consolidated revenue of 2.918 billion yuan, a year-on-year increase of 21.43%, with a net profit attributable to shareholders of 178.91 million yuan, up 26.25% [6] - For the first quarter of 2025, the company reported consolidated revenue of 881 million yuan, a 6.41% increase year-on-year, and a net profit of 63.46 million yuan, up 22.19% [6] - The company aims to achieve consolidated revenue of no less than 3 billion yuan in 2025 [2][5] Group 4: Product Development and Innovation - The company is focusing on increasing the localization rate of its mining vehicle components, which are currently primarily sourced from abroad [1] - The TR50E and TR100E models have been successfully implemented in the cement industry, significantly reducing costs and achieving zero emissions [6] - The company is actively following national policies promoting equipment upgrades and replacements [6]

以下文章来源于动脉网 ，作者赵泓维 作者 | 赵泓维 来源 | 动脉网 （ID：vcbeat） 医疗设备厂商的日子近来不太好过。 国信证券的一份调研报告显示：2024年上半年全国医疗设备中标总金额仅为520亿元， 同比降幅高达35%。 动脉网 . 动脉网（www.vbdata.cn）聚焦于技术驱动下生命健康领域产业创新和变革的报道与研究。 设备销量放缓。 其中，磁共振、CT、超声、内窥镜、监护设备的形势尤为严峻，以上品类中标金额分别 为65亿、65亿、60亿、45亿和10亿；对应降幅-40%、-40%、-40%、-50% 和-50%，每一类设备的销量都几近腰斩。 2023Q1-2024Q2医疗设备重要品类中标金额情况（单位：亿元；数据来源：国信证 券） 宏观下的萧条给予了每一家企业同等体验。无论国产龙头迈瑞联影，还是跨国巨擘 GPS，这半年间交出的答卷都不尽如人意。 如今凛冬已至，医学设备的转机还有多远？ 设备销量放缓，企业到底承了多少压？ 医疗设备市场急速缩紧背后，一个最为明显的原因是2023年年中开启的医药反腐风暴。 作为此次行动的重灾区，医疗器械相关的违法操作层出不穷。很多医院管理者通过虚报 费用、收受 ...